Fig. 1: Upregulation of PIM1 expression and development of EMT are observed in osimertinib-resistant cells. | Cell Death & Disease

Fig. 1: Upregulation of PIM1 expression and development of EMT are observed in osimertinib-resistant cells.

From: PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Fig. 1

A, B The IC50 values of parental (H1975 and PC9) and osimertinib-resistant (H1975/OR and PC9/OR) cells treated with osimertinib. Data are presented as mean ± SD, ****p < 0.0001, Student’s t test. C Morphology of H1975 and H1975/OR cells. D Heatmaps of DEGs related to mesenchymal markers and epithelial markers. E EMT pathway enrichment in H1975 cell lines as determined by GSEA. F Immunofluorescent staining of PIM1 and Vimentin in H1975/OR and PC9/OR cells compared with parental cells. Scale bar, 50 μm. G Detection of expression levels of EMT-associated molecules before and after osimertinib resistance by immunoblotting. H The fluorescence intensity of lung metastases was measured. Data are presented as mean ± SD, *p < 0.05, Student’s t test. I Macroscopic appearances of lung images of each group, black arrows indicate the tumor nodules. Lung metastasis nodules were confirmed by H&E staining. The number of lung metastatic nodules was measured. Data are presented as mean ± SD, **p < 0.01, Student’s t test.

Back to article page